Eledon Pharmaceuticals, Inc.

ELDN Nasdaq SEC CIK 1404281
Follow Eledon Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.9M +77.5% vs same quarter last year
EPS, diluted −$0.03 +85.7% vs same quarter last year
Operating cash flow −$19M −31.1% vs same quarter last year
Operating income −$21.7M −13.6% vs same quarter last year
Net income by quarter
−$44.6M
−$6.5M
−$11.2M
−$17.5M
−$10.4M
−$39M
−$31.6M
−$3.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$45.6M
FY24-−$36.2M
FY23-−$116.5M
FY22-−$88M
FY21-−$34.5M
FY20-−$22.8M
FY19-−$16M
FY18-−$14.1M
FY17-−$13.1M
FY16$0−$5.7M
FY15$0−$45.1M
FY14$0−$23.3M
FY13$0−$15.7M
FY12$0−$9.6M
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16−$4.9M
FY15−$41.8M
FY14−$21.1M
FY13−$15.5M
FY12−$9.3M
FY11-